ERRATUM

In the article by Bertuglia, published in the September 2005 issue of Critical Care Medicine, the figures should appear as follows.

Figure 2.: Diameter of A2–A3 and A4 arterioles in the groups treated with saline (I/R), 2,2′-hydroxynitrosohydrazino bis-etanamine, DETA-NO (DN), ultrasound (US), and US in the presence of Sono Vue (SV) or Levovist (LV) at baseline (Bsl) and after reperfusion. Values are mean ± sd; *p < .001 vs. baseline; °p < .05 vs. the I/R group.

Figure 3.: Modifications in the red blood cell (RBC) velocity, flow, and shear stress of A2–A3 and A4 arterioles in the groups treated with saline (I/R), 2,2′-hydroxynitrosohydrazino bis-etanamine, DETA-NO (DN), ultrasound (US), and US in the presence of Sono Vue (SV) or Levovist (LV) at baseline (Bsl) and after reperfusion. Values are mean ± sd; *p < .001 vs. baseline; °p < .05 vs. I/R; °p < .05 vs. the US group.

Figure 4.: The percentage change of the perfused capillary length (PCL) after reperfusion in the groups treated with saline (I/R), 2,2′-hydroxynitrosohydrazino bis-etanamine, DETA-NO (DN), ultrasound (US), and US in the presence of Sono Vue (SV) or Levovist (LV). Values are mean ± sd; n = 10 experimental observations for each entry; p < .05 vs. the I/R group; °p < .05 vs. the US group.

Figure 6.: Lipid peroxide measurements in the systemic blood of hamsters treated with saline (I/R), 2,2′-hydroxynitrosohydrazino bis-etanamine, DETA-NO (DN), ultrasound (US) and US in the presence of Sono Vue (SV) or Levovist (LV) at baseline and after 15, 30, and 45 mins of reperfusion. Values are mean ± sd; *p < .05 vs. baseline; °p < .05 vs. the I/R group.

Figure 7.: Vascular permeability (normalized to baseline) in the groups treated with saline (I/R), 2,2′-hydroxynitrosohydrazino bis-etanamine, DETA-NO (DN), ultrasound (US), and US in the presence of Sono Vue (SV) or Levovist (LV) at baseline (Bsl, US, SV, LV) and after reperfusion (USR, SVR, LVR). Values are mean ± sd; *p < .001 vs. baseline; °p < .001 vs. the US and I/R groups.

Figure 8.: The number of adherent leukocytes/100 μm venules in the groups treated with saline (I/R), 2,2′-hydroxynitrosohydrazino bis-etanamine, DETA-NO (DN), ultrasound (US), and US in the presence of Sono Vue (SV) or Levovist (LV) at baseline (Bsl) and after reperfusion. Values are mean ± sd; n = 25 experimental observations for each entry, *p < .001 vs. baseline; °p < .05 vs. the I/R group; °p < .05 vs. the US group.

The author regrets the error.